[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-transplant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-transplant-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,78,111,133,160,182,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100641683","impact-of-culture-of-perfusion-fluid-on-donor-derived-infection-management-and-outcome-in-liver-and-kidney-transplant-100641683",false,"NCT07651137","Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant","PREVENT","Inclusion Criteria:\n\n* Adult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBO clinical center during the specified study periods\n* Availability of graft preservation fluid culture results\n* Signed informed consent\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":19,"type":20},1400,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible donor-derived infections (infections transmitted from the donor organ).\n\nThe study will include all liver and kidney transplant recipients with available perfusion fluid culture results from 2021 until the start of the study (retrospective phase) and for two years after study initiation (prospective phase).\n\nThe study will assess how often high-risk microorganisms are identified in perfusion fluid, whether these findings are associated with complications or infections in recipients, and whether they affect patient outcomes, including mortality.",[24,25,26,27,28,29],"Liver Transplant Infection","Kidney Transplant Infection","Liver Transplant","Kidney Transplant","Bacterial Infection","Donor-derived Infection",[31,32,33,34,35,36,37,38,39],"perfusion fluid","graft","transplantation","transplant recipients","infections","donor-derived infections","liver transplant","kidney transplant","preservation fluid","NOT_YET_RECRUITING","2026-06-11",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":20},"2026-09-01",{"date":48,"type":20},"2029-08-31",{"name":50,"class":51},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":52},"100547381","phase-3-letermovir-prevymis-for-cmv-in-kidney-and-pancreas-transplant-recipients-100547381","NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients","An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+\u002FR-) Kidney and Kidney\u002FPancreas Transplant Recipients","Inclusion Criteria:\n\n* undergone kidney or simultaneous kidney\u002Fpancreas transplant\n* high-risk CMV serostatus (D+\u002FR-) at time of transplant\n* develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)\n* demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening\n* able to provide informed consent to participate\n\nExclusion Criteria:\n\n* contraindication to letermovir or its excipients\n* develop ganciclovir-resistant CMV infection\n* currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent\n* unable or unwilling, in the opinion of the Investigator, to comply with the protocol\n* pregnant or breastfeeding",{"count":61,"type":20},90,"INTERVENTIONAL",[64],"PHASE3","This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney\u002Fpancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.",[67,25,68],"Cytomegalovirus Infections","Pancreas Transplant","RECRUITING","2026-06-09",{"date":41,"type":44},{"date":73,"type":44},"2024-08-08",{"date":75,"type":20},"2027-08",{"name":77,"class":51},"University of Wisconsin, Madison",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":62,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100464231","phase-3-a-trial-to-treat-polyomavirus-infections-bkpyv-in-kidney-and-simultaneous-kidney-pancreas-transplant-recipients-100464231","NCT05325008","A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients","An Adaptive Randomised Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney Pancreas Transplant Recipients","BEAT-BK","Inclusion Criteria:\n\n1. Aged 2 years or above\n2. Have received a kidney or simultaneous pancreas-kidney transplant\n3. Have BKPyV-Viremia (detected by RT-PCR) with a viral count ≥ 5,000 copies per mL, or histological confirmation of BKPyVAN, within 3 weeks prior to randomisation.\n4. Be able to provide informed consent or consent given by a parent or guardian (if age \\\u003C18 years) or other authorised person\n\nExclusion Criteria:\n\n1. Contraindications to receiving IVIG as a treatment\n2. Current active acute rejection (≤ 3 months prior)\n3. Treating clinicians would regard as unsafe to be enrolled\n4. Limited life expectancy (\\\u003C 12 months)\n5. Receiving Belatacept as part of their immunosuppression protocol\n6. Currently undergoing or who have previously received, viral-specific T-cell therapy for BK viremia\n7. Prior infection and treatment for BKPyV-Viremia\n8. Received IVIG treatment in the past with last IVIG treatment \\\u003C 4 weeks prior to randomisation","2 Years",{"count":88,"type":20},280,[64],"BEAT-BK will see the effect of immunosuppression reduction\u002Fmodification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and simultaneous kidney pancreas transplant recipients with polyomavirus infections (BKPyV).",[92,25,93],"BK Viremia","Kidney Transplant Failure and Rejection",[95,96,97,98,99,100],"Kidney transplantation","Intravenous immunoglobulin","Virus","Nephropathy","Clinical trial","Nephrology","2026-06-05",{"date":103,"type":44},"2026-06-08",{"date":105,"type":44},"2023-08-18",{"date":107,"type":20},"2029-06-30",{"name":109,"class":51},"The University of Queensland",13,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":62,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100493696","phase-3-effectiveness-of-an-immune-guided-cytomegalovirus-infection-preventive-strategy-compared-to-a-universal-prophylactic-strategy-in-renal-transplant-patients-100493696","NCT05708508","Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients","CYTOPREV","Inclusion Criteria:\n\n* Renal transplant patient for 1 to 12 days\n* CMV seropositivity on the day of transplantation: IgG threshold =6 AU\u002FmL CMIA CMV IgG, Architect i4000 (Abbott)) (Serology performed on D0, before the transplant)\n* Non-depleting inducing immunosuppressive treatment (Basiliximab) (implementation before the transplant)\n* Affiliation to a social security scheme\n* Patient having read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n* Active CMV infection (detectable CMV DNAemia - peripheral CMV DNAemia ≥ 305 IU\u002FmL)\n* Patient with hypersensitivity to valganciclovir, ganciclovir, aciclovir or valaciclovir or to any of the excipients\n* Lympho-depleting inducing immunosuppressive treatment (antithymoglobulins)\n* Neutropenia (neutrophils \\\u003C 500\u002Fmm3) or thrombocytopenia (platelets \\\u003C 25,000\u002Fmm3) or anemia (hemoglobin \\\u003C 8G\u002FL) identified on routine care samples taken on the day of inclusion","75 Years",{"count":120,"type":20},144,[64],"Cytomegalovirus (CMV) establishes a chronic infection in 60% of the general population. In renal transplant recipients, it is responsible for morbidities occurring mainly in the first 6 months after transplantation. These include viral reactivations linked to immunosuppressive treatment inhibiting the anti-CMV T lymphocyte response. CMV infection, a sign of uncontrolled viral replication, is defined by the detection of viral DNA in the peripheral blood (DNAemia). CMV disease is defined as the association of an infection and symptoms attributable to the virus.\n\nIn transplant recipients carrying the virus before transplantation (positive serology: CMV+), two infection prevention strategies are recommended: either close monitoring of DNAemia with antiviral treatment in the event of positive detection (pre-emptive strategy), or antiviral treatment for the first 3 months following the transplant (prophylactic strategy). Both strategies result in the occurrence of CMV infection in 15 to 20% of patients within the first 6 months, with the majority of events occurring between 3 and 6 months.\n\nNumerous studies show that the evaluation of the anti-CMV T lymphocyte response, either before (D0) or early after transplantation (D15), or when antiviral prophylaxis is stopped, allows the identification of patients at risk of CMV infection. No study has yet demonstrated the contribution of such an evaluation in a preventive strategy.",[25],"2026-02-13",{"date":126,"type":44},"2026-02-17",{"date":128,"type":44},"2024-03-28",{"date":130,"type":20},"2027-04",{"name":132,"class":51},"University Hospital, Rouen",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":62,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100624287","phase-2-prediction-and-prevention-of-bloodstream-infections-after-kidney-transplantation-100624287","NCT07407673","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study","PREDICT","Inclusion Criteria:\n\n* Adult (\\>18 years) KTx recipients at high risk of BSI in the first year post-KTx.\n\nRecipients at high risk of BSI will be defined as recipients belonging to a group with a predicted BSI incidence of 25% in the first year post-transplantation by the prediction model.\n\nExclusion Criteria:\n\n* Recipients who cannot give informed consent or have contraindications for pivmecillinam treatment, including allergy to beta-lactamase antibiotics.",{"count":142,"type":20},150,[144],"PHASE2","Background: Kidney transplant (KTx) recipients receive life-long immunosuppression, which increases the risk of severe infections. Bloodstream infections (BSI) are common after transplantation and are associated with high mortality and morbidity. Prophylactic antibiotic treatment of all KTx recipients does not provide overall benefit, but a personalized strategy of prophylactic treatment of KTx recipients at high risk of BSI with targeted antibiotics has not been assessed.\n\nPrimary aim: To determine if prophylactic pivmecillinam in high-risk KTx recipients decreases the incidence of Enterobacterales BSI in the first 1-6 months post-transplantation.\n\nSecondary aim: To assess if prophylactic pivmecillinam reduces all-cause mortality, hospital admissions, graft loss, changes in the gut and urine resistome and microbiome, and increases quality of life in high-risk KTx recipients.\n\nDesign and target group: Multi-center double-blinded randomized controlled trial of 150 KTx recipients at high risk of BSI who will be randomized 1:1 to either pivmecillinam 400 mg once daily or placebo from months 1-6 post-transplantation. KTx recipients will be included from Rigshospitalet, Aarhus University Hospital and Odense University Hospital. 60 participants in each study arm will provide urine and stool samples at randomization and at the end of intervention for metagenomic sequencing of the bacterial microbiome and resistome.\n\nPerspectives: This trial will provide evidence necessary to assess if KTx recipients at high risk of BSI benefit from targeted prophylactic antibiotics and address a critical knowledge gap of how to reduce mortality and morbidity due to BSI after KTx. The study will also serve as proof-of-concept for a personalized approach to infection prevention in other populations at high risk of severe infections.\n\nResults from the study may easily be implemented since there is already a clinical set-up for prevention of viral infections in KTx recipients.",[25,147],"Bloodstream Infection",[149],"Prevention of bloodstream infection after kidney transplantation","2026-02-05",{"date":152,"type":44},"2026-02-12",{"date":154,"type":20},"2027-01-01",{"date":156,"type":20},"2029-07",{"name":158,"class":51},"Susanne Dam Nielsen, MD, DMSc",3,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":52},"100400480","sars-cov-2-infection-in-kidney-transplant-recipients-a-brazilian-multicenter-study-100400480","NCT04494776","SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Infection (COVID-19) in Kidney Transplant Recipients: a Brazilian Multicenter Study","Inclusion Criteria:\n\n1. Kidney transplant recipients, which may be multi-organ recipients, transplanted in any follow-up period;\n2. Positive diagnostic test for COVID-19 (detection of viral load, test for detection of antigens or tests for detection of antibodies);\n3. Outpatient or hospital management;\n4. Adults and children.\n\nExclusion Criteria:\n\n\\-",{"count":168,"type":20},500,"COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly contagious viral disease, the condition of which main clinical symptoms are characterized by fever and respiratory symptoms. Evidence indicates to worse outcomes in patients with pre-existing diseases, such as diabetes, arterial hypertension, heart disease, pneumopathies, chronic kidney disease, and immunodeficiencies. Recipients of kidney transplants make prolonged use of immunosuppressive drugs to inhibit the acquired immune response, notably the activity of lymphocytes. Due to this potential to modulate the immune and inflammatory response, it is speculated that the clinical and laboratory condition of COVID-19 in these patients is atypical. Preliminary evidence suggests worse outcomes of COVID-19 in immunosuppressed patients, as carriers of cancer. However, information on kidney transplant recipients is insufficient. So far, only reports of the case are available in the literature with different clinical presentations and outcomes. The aim of this study is, therefore, to characterize the demographics, clinical and laboratory conditions, and the outcomes of COVID-19 in kidney transplant recipients in a national multicenter cohort.",[171,25],"SARS-CoV-2 Infection",[171,25,27],"2024-11-07",{"date":175,"type":44},"2024-11-08",{"date":177,"type":44},"2020-05-21",{"date":179,"type":20},"2025-04-02",{"name":181,"class":51},"Helio Tedesco Silva Junior",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":62,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100485166","phase-3-efficacy-of-7-days-versus-14-days-of-antibiotic-therapy-for-acute-pyelonephritis-in-kidney-transplant-recipients-a-multicentre-randomized-non-inferiority-trial-100485166","NCT05597540","Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.","SHORTCUT","Inclusion Criteria:\n\n* Age \\>18 years KTR\n* APN defined by: fever (T°≥38°C) (with or without clinical signs and\u002For symptoms of UTI) and pyuria (≥10\\^4 white blood cells\u002FmL or ≥10\u002Fmm3) and positive urine culture (uropathogen ≥10\\^3 CFU\u002FmL susceptible to the empirically administrated antibiotic)\n* No confirmed or suspected febrile non urinary bacterial infection\n* No urologic\u002Frenal complication at baseline imaging (abscess, obstruction...)\n* Favourable early response to antibiotic treatment:48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen) defined by: T°\\\u003C38°C and improvement (or resolution) of signs and\u002For symptoms of urinary tract infection if present at diagnosis\n* Written informed consent\n\nExclusion Criteria:\n\n* Severe or complicated condition\n\n  * Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, septic shock, current or impeding respiratory failure, acute heart or liver failure\n  * Admission or stay in intensive care unit at baseline\n  * Obstruction of the urinary tract\n  * Renal, perinephric or prostatic abscess\n* Prior inclusion in this study\n* Current participation to another interventional study\n* Dual antibiotic therapy (prophylactic antibiotic such as cotrimoxazole allowed) (only 1 dose of aminoside is allowed before randomization)\n* First month post transplantation\n* Current indwelling catheter (including bladder catheter, ureteral stents, percutaneous nephrostomy tubes)\n* Neurogenic bladder\n* Enterocystoplasty\n* Immunodeficiency or immunosuppressive therapy not related to kidney transplantation including hematologic malignancy, cancer, asplenia, neutropenia\\\u003C500 neutrophils\u002Fmm3\n* Pregnancy, breastfeeding\n* Hypersensitivity or previous severe adverse drug reaction to the antibiotic therapy\n* Unable or unwilling, in the judgment of the investigator, to comply with the protocol\n* Life expectancy\\\u003C1 month\n* Patient under legal guardianship or without healthcare coverage\n* Homeless patient\n* Women with childbearing potential not using adequate contraception",{"count":190,"type":20},470,[64],"Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations for sepsis. Acute transplant pyelonephritis are the most common complications occurring in more than 20% of patients, mainly in the first year after transplantation. They are associated with an increased risk of acute kidney rejection and long-term kidney graft dysfunction. Gram-negative bacteria, mainly E. coli, account for more than 70% of UTI in KTR. As those infections are favoured by urinary tract modifications\u002Fdefects and immunosuppression, they are often recurrent and necessitate repeated courses of antibiotics. Selective pressure due to antibiotic consumption, along with frequent hospital admissions and immunosuppression, are well known risk factors for the development of antibiotic resistant infections. Multidrug (MDR)- or extensively (XDR)- drug resistant Enterobacteriaceae including ESBL- or carbapenemase-producing organisms, are thus increasingly observed in transplant units and represent a global threat as very few new antibiotics are expected in the next decade.\n\nOne main strategy to limit antimicrobial resistance is to reduce the duration of antibiotic treatment. A 7 day-course is recommended for simple acute pyelonephritis (APN) treated with fluoroquinolones or parenteral B-lactams, prolonged up to 10 or 14 days in the presence of underlying disease at risk of complications. Most KT teams treat patients between 14-21 days as recommended by American guidelines. However, the need to extend treatment duration in immunosuppressed patients is a poorly defined concept and the optimal duration of treatment for APN in KTR is not known as these patients are excluded from most studies.\n\nAs there is an urgent need to reduce antibiotic consumption in this population at high risk of developing infections due to resistant pathogens, the hypothesis is that a 7 day-treatment is sufficient to cure APN with good clinical response after 48h of treatment in KTR and is as effective as 14 days.",[194,25],"Pyelonephritis Acute",[196,197],"antibiotic therapy","duration of antibiotic treatment reduction","2024-05-26",{"date":200,"type":44},"2024-05-29",{"date":202,"type":44},"2024-02-22",{"date":204,"type":20},"2027-08-22",{"name":206,"class":51},"Assistance Publique - Hôpitaux de Paris",9,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":52},"100544110","use-of-wearables-to-detect-infections-in-kidney-transplant-recipients-100544110","NCT06364618","Use of Wearables to Detect Infections in Kidney Transplant Recipients","Use of Continuous Biomonitoring for Detection of Infectious Complications in Kidney Transplant Recipients","RENALERT","Inclusion Criteria:\n\n* kidney transplant recipient\n* age 18 years or more\n* kidney allograft function (eGFR based on CKD-EPI more than 15ml\u002Fmin\u002F1.73m2)\n\nExclusion Criteria:\n\n* recipient of another transplanted organ\n* terminal failure of another organ (heart, liver, lung)\n* diabetes mellitus type 1\n* pregnant or breastfeeding woman\n* refusal to give informed consent",{"count":217,"type":20},200,"The goal of this observational study is to develop a machine learning algorithm for early detection of infections in kidney transplant recipients using data recorded by wearable digital health technologies.\n\nThe main questions it aims to answer are:\n\n1. What are the biometric data pattern changes in impending infections?\n2. What accuracy the machine learning algorithm can achieve?\n\nParticipants will be given\u002Fuse their own wearable device that will record biometric data. Any infection event will be recorded and an algorithm will be trained to recognize changes in biometric data preceding symptomatic infection.",[25],[221,222,223,224,225,226],"biometric data","continuous monitoring","machine learning","early alert system","infection","kidney transplantation","2024-04-09",{"date":229,"type":44},"2024-04-15",{"date":231,"type":20},"2024-09-01",{"date":233,"type":20},"2027-12",{"name":235,"class":236},"Institute for Clinical and Experimental Medicine","OTHER_GOV"]